We hypothesize that, because Ad5AMUC_RSV-NIS CRAd harbors the NIS gene, it should improve the therapeutic value of the CRAd by allowing multimodal therapy in a single agent combining viral-mediated tumor lysis as well as radioiodine-mediated therapy. Here, SLC5A5 is linked to neoplasm.